Abpro Holdings, Inc.

Abpro Holdings, Inc., trading under the ticker ACAB, is a biopharmaceutical company focused on the development of multi-specific antibody therapeutics targeting cancer and other serious diseases. The company went public through a SPAC business combination, with its shares listed on Nasdaq. The April 2023 8-K filing reflects activity during the post-merger phase of the company's public market lifecycle. Abpro operates within the life sciences and biotechnology sector, applying its proprietary antibody engineering platform to advance a pipeline of differentiated oncology candidates. For complete filing history, sponsor details, and real-time SPAC deal tracking on ACAB and hundreds of other vehicles, sign up for full data access at SpacDesk.